Shuttle Pharmaceuticals licenses IP for prostate cancer biomarker program

Shuttle Pharmaceuticals has entered into an exclusive agreement to license certain intellectual property from Georgetown University to advance Shuttle Pharma’s predictive biomarker program for prostate cancer. The intellectual property was originally developed through a collaboration of Shuttle Pharma scientists with investigators from Georgetown University. Shuttle Pharma’s predictive marker strategy is to develop a predictive diagnostic test for prostate cancer patients who are considering elective radiation therapy which will allow them to assess their risk for treatment success or failure, while informing therapeutic decision making and follow-up management. Shuttle Pharma scientists have collaborated with investigators from Georgetown University to complete Phase I and Phase II NIH SBIR contracts to develop predictive biomarkers of radiation therapy outcomes and late effects. Shuttle Pharma will also seek to leverage eligibility to apply for project bridge funding via an NIH Phase IIb SBIR mechanism.